AstraZeneca PLC (AZN)vsEstablishment Labs Holdings Inc (ESTA)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
ESTA
Establishment Labs Holdings Inc
$74.31
-2.85%
HEALTHCARE · Cap: $2.08B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 26226% more annual revenue ($60.44B vs $229.58M). AZN leads profitability with a 17.2% profit margin vs -19.1%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
ESTA
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
-17.9%
Fair Value
$61.70
Current Price
$74.31
$12.61 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 44.7% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Trading at 148.6x book value
ROE of -295.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : ESTA
The strongest argument for ESTA centers on Revenue Growth. Revenue growth of 44.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : ESTA
The primary concerns for ESTA are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 17.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while ESTA is a hypergrowth play — different risk/reward profiles.
ESTA carries more volatility with a beta of 1.12 — expect wider price swings.
ESTA is growing revenue faster at 44.7% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 30/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Establishment Labs Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for cosmetic and reconstructive plastic surgery. The company is headquartered in Alajuela, Costa Rica.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?